| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $25,824 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Francis Knuettel II | CEO, Pres., CFO, Treas & Secty | 4 | $15,999 | 0 | $0 | $15,999 |
| Malamut Richard | director | 1 | $9,825 | 0 | $0 | $9,825 |
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Over the last 12 months, insiders at Channel Therapeutics Corporation have bought $25,824 and sold $0 worth of Channel Therapeutics Corporation stock.
On average, over the past 5 years, insiders at Channel Therapeutics Corporation have bought $25,824 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Francis Knuettel II (CEO, Pres., CFO, Treas & Secty) — $15,999. Malamut Richard (director) — $9,825.
The last purchase of 3,500 shares for transaction amount of $3,395 was made by Francis Knuettel II (CEO, Pres., CFO, Treas & Secty) on 2024‑09‑13.
| 2024-09-13 | Francis Knuettel II | CEO, Pres., CFO, Treas & Secty | 3,500 0.0922% | $0.97 | $3,395 | +9.67% | ||
| 2024-09-12 | Francis Knuettel II | CEO, Pres., CFO, Treas & Secty | 1,700 0.0448% | $0.97 | $1,649 | +3.10% | ||
| 2024-09-12 | Malamut Richard | director | 10,400 0.2668% | $0.94 | $9,825 | +3.10% | ||
| 2024-09-11 | Francis Knuettel II | CEO, Pres., CFO, Treas & Secty | 5,500 0.1404% | $0.94 | $5,170 | +5.16% | ||
| 2024-09-10 | Francis Knuettel II | CEO, Pres., CFO, Treas & Secty | 6,500 0.1571% | $0.89 | $5,785 | +9.78% |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |